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Abstract
Importance—Within ten years after breast cancer diagnosis, 5% of patients develop contralateral 
primary breast cancer (CBC). Randomized trials have found that tamoxifen and aromatase 
inhibitors (AIs) reduce CBC risk. However, little is known about the magnitude and duration of 
protective effects within the context of “real world” clinical management settings, where varying 
durations and gaps in treatment are common.
Objective—To determine the influence of adjuvant tamoxifen and AIs on CBC risk within the 
general community setting.
Design—Retrospective cohort study of CBC risk among breast cancer patients diagnosed with a 
first primary unilateral invasive breast cancer at Kaiser Permanente Northwest or Colorado from 
1990–2008 and followed through 2011.
Setting—General community health care plan.
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Participants—7,541 breast cancer patients, ages 24–85 years, diagnosed with invasive breast 
cancer, and survived for ≥one year.
Exposures—Adjuvant tamoxifen and AIs assessed using prescription records.
Main Outcome Measure—Incident contralateral breast cancer.
Results—Over a median(range) of 6.3(1.0–20.9) years, 248 women developed CBC. CBC risk 
decreased significantly with increasing tamoxifen duration. In current users, the relative risk (RR) 
per year of use was 0.76 (95%CI:0.64–0.89), with a 66% reduction for 4 years of use (RR=0.34, 
95%CI:0.29–0.40). Risk reductions were slightly smaller for past users, but still significant 5+ 
years after stopping (RR/year use=0.85, 95%CI:0.71–0.995). AI use without tamoxifen was also 
associated with reduced CBC risk (RR=0.48, 95%CI:0.22–0.97). Risk reductions were most 
apparent among women whose primary and CBCs were ER-positive.
Conclusions and Relevance—We found that tamoxifen reduced CBC risk during treatment 
and after cessation, with risk progressively decreasing as tamoxifen duration increased. Tamoxifen 
use for 4+ years was estimated to result in the prevention of three CBCs per 100 women by 10 
years following an ER-positive first breast cancer, an absolute risk reduction which is consistent 
with findings from clinical trials. If adjuvant endocrine therapy is indicated for breast cancer 
treatment, our findings, in concert with trial data, suggest that women should be encouraged to 
complete the full course.
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Introduction
Increasing incidence of estrogen receptor (ER)-positive breast cancer in the U.S. in concert 
with the aging population and improved survival have resulted in an increased number of 
women at risk of developing second primary contralateral breast cancer (CBC).1 Ten-year 
cumulative incidence of CBC is approximately 5%.2 Randomized clinical trials have 
consistently demonstrated that tamoxifen reduces risk of primary cancer recurrence, 
improves survival, and reduces CBC risk .3,4 An Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) pooled analysis of 20 trials examining long-term effects of five years of 
adjuvant tamoxifen versus no tamoxifen found an absolute reduction in CBC at 15 years of 
3.2% among women whose initial diagnoses were ER-positive; tamoxifen did not 
significantly alter CBC incidence among women with ER-negative primary tumors.3 
Amassing trial data also indicate lower CBC risk with aromatase inhibitors (AIs).5,6
Despite strong evidence from trials, little is known about the magnitude and duration of 
protective effects within real world treatment scenarios, where varying durations and gaps in 
treatment are common. Observational studies have reported marked reductions in CBC risk 
with use of tamoxifen or other unspecified endocrine therapies;7–17 however, most have not 
directly examined therapy duration and persistence of effects.7–12,14–17 Further, 
observational studies have offered conflicting evidence as to whether associations differ 
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according to ER status of the CBC,9,12 and none has reported on the influence of AIs on 
CBC risk.
We undertook an investigation of the influence of adjuvant tamoxifen and AIs on CBC risk 
in a cohort of women diagnosed with invasive breast cancer within the Kaiser Permanente 
health plan. Kaiser offers several advantages for studying these associations, including the 
long-term systematic follow-up of a large number of breast cancer patients with electronic 
prescription records, facilitating characterization of persistence of effects of varying 
treatment durations while accounting for treatment gaps.
Methods
Study Population and Data Collection
We developed a retrospective cohort of patients (n=8,308), diagnosed with a first primary 
unilateral invasive breast cancer at Kaiser Permanente (KP) Northwest (n=4,665, 1990–
2008) or Colorado (n=3,643, 1994–2008), who survived and remained at CBC risk for ≥one 
year (Figure 1). We excluded 342 patients with contralateral breast removal at initial surgery, 
125 initially diagnosed with metastatic disease, 98 not treated with breast surgery, and 202 
diagnosed at ages 85+ (Figure 1), resulting in an analytic cohort of 7,541 patients.
This study was approved by the NCI Special Studies Institutional Review Board (IRB) and 
KP Northwest and Colorado IRBs. A waiver of written informed consent was granted based 
on the minimal risk of this linkage-based research.
Exposure and Outcome Assessment
Treatment with tamoxifen, AIs, other hormonal agents, chemotherapeutic agents, and 
radiotherapy was obtained from electronic KP prescription and medical records. Treatment 
courses were defined separately for tamoxifen and AIs and consisted of therapy without a 
gap in prescription coverage of ≥90 days. Women were considered users of adjuvant 
endocrine therapy if they had accumulated ≥90 days of therapy during any one treatment 
course following the first primary cancer diagnosis. Due to the relatively recent introduction 
of AIs in this cohort, we assessed ever use, but could not yet evaluate their recency or 
duration. Current tamoxifen use was defined as tamoxifen use within the past 30 days 
whereas former use was defined as ≥30 days. Time since last tamoxifen use was calculated 
from the end of the last tamoxifen course during the follow-up period; 15% of patients 
treated with tamoxifen had ≥2 courses.
Patient and clinical characteristics, including race, height, weight (available after 1996 in 
NW and after 2000 in CO), and tumor characteristics, were obtained from electronic medical 
records. Measured height and weight were used to calculate BMI (kg/m2). Second cancer 
diagnoses and vital status were determined from the KP tumor registry.
Statistical Analysis
We used multivariable Poisson regression models to estimate relative risks (RRs) and 95% 
confidence intervals (CIs) for CBC risk associated with endocrine therapy. Study entry was 
one year after diagnosis of the first breast cancer, and person-years accrued until the earliest 
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of the following events: CBC diagnosis, other second cancer diagnosis, death, last tumor-
registry follow-up, exit from KP plan, or end of study (KP Northwest:12/31/2010; Colorado:
2011).
Tamoxifen and AIs were treated as time-dependent exposures. We evaluated risk in relation 
to a combination of tamoxifen duration in years (continuous variable, log linear trend) and 
time since last use (i.e., current use and former use with <3 years, 3-<5 years and 5+ years 
since last use); the reference group was defined as those who had never used tamoxifen or 
used tamoxifen for <90 days. Among former tamoxifen users, we also assessed risk in 
relation to categories of tamoxifen duration of 90 days-<1 year, 1-<4 years, and 4+ years, 
using cut points based on the cohort distribution of cumulative tamoxifen exposure. 
Sensitivity analyses evaluating CBC risk associated with the first tamoxifen course yielded 
similar results and are not shown. Poisson regression models were stratified by covariates 
that we had identified a priori, including study site, age and AJCC stage at diagnosis, ER 
status of initial tumor, time since initial breast cancer in yearly categories up to 15 years or 
more, and diagnosis year. We also adjusted models simultaneously for AI use (with or 
without tamoxifen), chemotherapy with an alkylating agent, and radiotherapy. As BMI was 
not associated with tamoxifen duration, it was not used in the adjustments.
In subgroup analyses, we evaluated associations by ER status and age (<50 vs. 50+ years, a 
proxy for menopausal status) at diagnosis of the initial breast cancer. We also examined risk 
according to ER status of the CBC.
Among women surviving 5+ years after a diagnosis of ER-positive breast cancer, we 
estimated cumulative incidence of CBC according to tamoxifen duration (no tamoxifen, 
tamoxifen duration <4 years (the median duration), and duration 4+ years), accounting for 
death and diagnosis of other second cancers as competing risks.18
P-values of <0.05 were considered statistically significant. All tests of significance were 
two-tailed. Analyses were performed using Epicure software (v2.1, Seattle, WA).19
Results
Patient characteristics associated with CBC and adjuvant tamoxifen therapy
The median(range) age at initial breast cancer diagnosis was 60.6(24.9–84.9) years. Women 
were predominantly white (93%)(Supplementary Table 1). Over a median(range) of 6.3(1.0–
20.9) years of follow-up, 248 women developed CBC (45 in-situ, 203 invasive). Compared 
to women who did not develop CBC, CBC cases had similar initial breast cancer stage, 
grade, histology, and ER status. Nearly 70% of CBC cases and non-cases were prescribed 
radiotherapy and approximately one-third were prescribed chemotherapy with an alkylating 
agent for initial treatment. However, during study follow-up, CBC cases were less likely to 
have been treated with endocrine therapy as compared with non-cases (51% vs. 65%).
Compared with non-users, tamoxifen users were slightly more likely to be white (95% vs. 
91%) and <50 years of age at initial diagnosis (22% vs. 19%)(Supplementary Table 2). 
Tamoxifen users were more likely to have initial diagnoses that were stage II, moderately 
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differentiated grade, and ER-positive. In addition, tamoxifen use was less common among 
women whose primary breast cancer had been diagnosed more recently.
Relationships between adjuvant endocrine therapy and CBC risk
Fifty-two percent of patients used tamoxifen with a median(range) duration of use of 
3.3(0.25–16.2) years. CBC risk decreased with increasing tamoxifen duration among current 
and former users (Figure 2, Supplementary Table 3). In current users, the RR per year of 
tamoxifen use was 0.76(95%CI:0.64–0.89) (Table 1), resulting in an estimated 66% RR 
reduction for 4 years of use as compared with non-users (RR=0.34, 95%CI:0.29–0.40). The 
risk reductions were slightly smaller for past users, but still significant 5+ years after 
stopping (RR/year use=0.85, 95%CI:0.71–0.995).
During the course of the study, 1,929 patients (26%) received AIs (typically anastrozole or 
less frequently letrozole), with increasing use in more recent calendar periods. AIs taken 
with (n=963) and without (n=966) tamoxifen were used for a median(range) duration of 
2.24(0.25–10.23) and 2.94(0.25–9.46) years, respectively. AI use without tamoxifen was 
associated with reduced CBC risk (AI users compared with non-users: RR=0.48, 95%CI:
0.22–0.97, n=10 CBC, Table 1). We did not have sufficient statistical power to evaluate these 
risks in more detail.
Subgroup analyses by ER status of the primary and contralateral breast cancers
Among women whose first cancer was ER-positive (n=5,951), findings were consistent with 
the overall cohort (Table 1). Likewise, when considering ER status of the subsequent CBC, 
risk of ER-positive CBC decreased significantly with increasing years of tamoxifen duration 
among current users (RR/year use=0.68, 95%CI:0.54–0.84) and among former users with <5 
years since last use as compared with non-users (RR/year use in those with <3 years since 
last use=0.79, 95%CI:0.67–0.91; RR/year use in those with 3-<5 years since last use=0.83, 
95%CI:0.70–0.98). Among women whose primary cancer was ER-positive, 31 were 
subsequently diagnosed with ER-negative CBC. Though based on small numbers, there was 
little indication that tamoxifen reduced ER-negative CBC risk, when evaluated using 
tamoxifen duration (Table 1) or when tamoxifen users were compared to non-users 
(RR=1.06, 95%CI:0.41–3.10).
Among women whose first primary cancer was ER-negative (n=1,236), 14.6% used 
endocrine therapy, for which no clear effects were observed (data not shown). Twenty-five of 
the CBCs were ER-positive and 13 were ER-negative. Among patients with a first ER-
negative cancer, tamoxifen was not associated with reduced risk even of ER-positive CBC 
(RR=1.97, 95%CI:0.50–6.39; n=4 CBC); however, the numbers of CBCs diagnosed within 
treatment groups were small.
Subgroup analyses by age of first breast cancer diagnosis
In separate analyses by age at initial diagnosis, findings among women who were 50+ years 
at initial diagnosis (Supplementary Table 4) were similar to those observed in the overall 
cohort. Among women whose first breast cancer was diagnosed at age <50 years, risk 
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reductions were similar for current and former users with <5 years since last use but based 
on only 53 CBC cases and not statistically significant.
Cumulative incidence of CBC
Figure 3 shows the estimated cumulative incidence of CBC adjusted for competing risks by 
tamoxifen use and duration among 3,732 women who survived 5+ years after a diagnosis of 
ER-positive first breast cancer. Among these patients, 67% used tamoxifen with a 
median(range) duration of use of 4.19(0.25–16.18) years. Patients who did not use 
tamoxifen had a 10-year cumulative incidence of CBC=4.9% (95%CI:3.3–6.5), whereas 
incidence was lower among those taking tamoxifen for <4 years (3.3%, 95%CI:2.1–4.6) and 
was lowest among those taking tamoxifen for 4+ years (1.6%, 95%CI:0.9–2.3). Among 
these 5+ year survivors, tamoxifen use for 4+ years was estimated to prevent three CBCs per 
100 women at 10 years following the first diagnosis. At 15 years post-diagnosis, use of 
tamoxifen for 4+ years was estimated to prevent 4 CBCs per 100 women.
Discussion
This retrospective analysis of over 7,500 U.S. patients with invasive breast carcinoma treated 
in a general community health care plan suggests that adjuvant tamoxifen and AIs 
significantly reduce CBC risk. We have supplemented clinical trial data by testing 
associations in an unselected group of patients, utilizing prescription records to accurately 
quantify the risk reduction in CBC per year of adjuvant tamoxifen use, and estimating the 
persistence of therapeutic effects in analyses accounting for gaps in therapy and multiple 
treatment courses. We found that tamoxifen protects against CBC while women are 
undergoing treatment, and after treatment has ceased. Among former users, the risk 
reduction was most apparent for those receiving tamoxifen for 4+ years, with protective 
effects persisting during the first five years after stopping. These associations were stronger 
among women whose first primary cancer was ER-positive.
The risk reductions in CBC associated with 4+ years of tamoxifen in this observational 
cohort are consistent with those found in clinical trials of women randomized to five years of 
tamoxifen.20,21 Whereas the standard “intention-to-treat” analysis in trials only evaluates the 
prescribed treatment period, we directly evaluated cumulative tamoxifen exposure over a 
wide range of durations (0.25–16.2 years) and observed progressive reductions in CBC risk 
with increasing duration. A systematic ASCO review concluded that women randomized to 
take tamoxifen therapy either indefinitely or for 10 years as compared with five years had 
lower CBC risk.22 Less than 5% of patients in our cohort received cumulative tamoxifen 
greater than five years; however, our findings are still an extension beyond prior 
observational cohorts, which only evaluated risk estimates for tamoxifen lasting ≥1 
year.8,9,13
As we have shown, persistence of protective effects of adjuvant tamoxifen on CBC risk 
likely depends on therapy duration, an issue not sufficiently addressed in prior observational 
studies.7–12,14–17 In the WECARE case-control study, significant protective effects of 
tamoxifen on CBC persisted for five years post-diagnosis; therapy duration was not directly 
examined.7 Two nested case-control studies found that taking tamoxifen for ≥12 months was 
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associated with decreased CBC risk, but persistence of the effect was not reported.8,9 Cohort 
studies have demonstrated substantial reductions in CBC risk with tamoxifen or other 
unspecified endocrine therapies.10–17 In the single cohort study to have evaluated the 
persistence of effects in relation to tamoxifen duration, no clear patterns emerged.13 This 
Danish study found that current, but not former, adjuvant tamoxifen was associated with 
reduced CBC risk.13 The lack of effect among former users could be due to shorter 
tamoxifen duration (median:1–2.5 years)13 relative to our U.S. patient population.
In contrast, findings from our observational study are remarkably consistent with a recent 
EBCTCG pooled analysis examining long-term effects of adjuvant tamoxifen.3 Similar to 
EBCTCG’s report of an absolute reduction in CBC at 15 years of 3.2%,3 we saw absolute 
reductions in CBC of 3.3% at 10 years and 4% at 15 years for 4+ years of tamoxifen versus 
no tamoxifen among ER-positive patients surviving 5+ years. Also consistent with 
EBCTCG’s pooled analysis,3 we found that tamoxifen did not appear to lower CBC 
incidence among women with ER-negative primary tumors, although our numbers were too 
small for precise evaluation. The agreement of our study with EBCTCG’s report regarding 
the effectiveness of tamoxifen strengthens evidence for a long-lasting reduction in CBC risk 
both within and outside of the clinical trial setting.
Just as tamoxifen has been shown to be most effective among women whose initial diagnosis 
is ER-positive, in our study as well as others,9,12,23 tamoxifen was particularly effective in 
reducing risk of ER-positive CBC. We and others12 have also shown that tamoxifen does not 
seem to significantly influence risk of ER-negative CBC; however, these findings conflict 
with those from a prior nested case-control study, which reported a 4.4-fold elevation in risk 
of ER-negative CBC (52 cases) associated with 5+ years of adjuvant tamoxifen.9 Although 
we had limited statistical power to evaluate risk of ER-negative CBC, confidence intervals 
for tamoxifen-associated ER-negative CBC risk were not consistent with an increased risk of 
the magnitude reported previously.
For decades, five years of tamoxifen was the standard adjuvant therapy for patients with ER-
positive tumors.24 More recently, AIs have provided an alternate therapeutic option for ER-
positive postmenopausal patients.6,25 In the 10-year analysis of the ATAC trial, women 
randomized to receive anastrozole versus tamoxifen experienced significantly lower CBC 
risk.26 The relatively recent introduction of AIs into clinical practice in our cohort precluded 
assessments of drug classes and persistence of effects of varying AI durations on CBC risk. 
This will be the subject of future investigations.
In the U.S., most observational studies evaluating the influence of tamoxifen on CBC risk 
have been designed as cross-sectional7 or nested8,9 case-control studies. A major strength of 
our retrospective cohort study is that it was conducted within a large, prepaid health plan 
that provided all aspects of care, including cancer treatment and provision of prescription 
medications. Furthermore, the cohort design allowed for absolute risk estimation, which is 
essential for clinical decision-making.
Despite these advantages, our study had several limitations. As our study observational, 
patients who used endocrine therapy for long durations may differ in some manner as 
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compared to never or short-term users. While we adjusted for multiple patient and clinical 
characteristics, the possibility of residual or unmeasured confounding exists. ASCO 
guidelines recommend that pre- or perimenopausal women who have hormone receptor-
positive breast cancer be offered adjuvant tamoxifen.22 We could not fully evaluate this issue 
as we lacked menopausal status. Using age <50 years as a proxy, we found that tamoxifen 
was weakly associated with reduced CBC risk only among current and former users with <5 
years since last use. Current clinical guidelines recommend that postmenopausal women be 
offered the choice of continuing tamoxifen or switching to an AI for 10 years of adjuvant 
endocrine therapy.22 Thus, despite the older age of our cohort, our findings demonstrating 
significant reductions in CBC risk with adjuvant tamoxifen (and AI) therapy are still relevant 
within the context of contemporary clinical guidelines.
Early reports of reduced CBC risk in adjuvant tamoxifen trials motivated its evaluation as a 
preventive agent and drew attention to the importance of the contralateral breast as a risk 
marker.27,28 Thus, our findings may have implications not only for women undergoing 
adjuvant therapy but also for breast cancer prevention. In a recent meta-analysis of 
tamoxifen prevention trials, breast cancer incidence was significantly reduced within the 
five-year active treatment period and the first five years after stopping.29 Our analysis of 
patients treated with adjuvant tamoxifen during a 20-year follow-up period might provide 
some clues as to the persistence of protection in the chemopreventive setting.
As the decision to elect contralateral prophylactic mastectomy increases in popularity, 
despite evidence suggesting no survival benefit over breast conservation,5,30 data from the 
general community setting on the effects of adjuvant endocrine therapy on CBC risk as well 
as on recurrence and death will be important. Non-adherence to adjuvant endocrine therapy 
has been attributed to multiple factors, including side effects and financial constraints.31–33 
Although tamoxifen has been available in a generic form since 2002, generic AIs were not 
available until 2010. Compared with brand-name users, AI-generic users have been shown to 
have increased adherence.33 Improved adherence to endocrine therapy has also been 
associated with patient-centered healthcare services.31 Thus, this is an opportune time for 
clinicians to engage in shared, informed decision-making with patients regarding the best 
treatment course. If adjuvant endocrine therapy is indicated for breast cancer treatment, our 
findings, in concert with trial data, suggest that women should be encouraged to complete 
the full course.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Inclusion and exclusion criteria for study participants. Women diagnosed with invasive 
breast cancer at Kaiser Permanente (KP) Northwest (1990–2008) or Colorado (1994–2008) 
were followed until the earliest of the following events: contralateral breast cancer diagnosis, 
other second cancer diagnosis, exited the KP plan, death, last tumor-registry follow-up, or 
end of study date (December 31, 2010 for KP Northwest or 2011 for KP Colorado).
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Relative risks (RR) and 95% confidence intervals (CI) for contralateral breast cancer 
associated with adjuvant tamoxifen by time since last use and duration of therapy, Kaiser 
Permanente Northwest and Colorado. Poisson models were stratified by study site (NW/
CO), age at diagnosis (<40, 40–49, 50–59, 60–69, 70+ years), stage at diagnosis (I, II, III, 
unknown stage), ER status of the initial tumor (positive, negative, unknown/indeterminate), 
time since initial breast cancer in yearly categories up to 15 years or more, and, to account 
for potential cohort effects, year of diagnosis (1990–94, 1995–99, 2000–04, 2005–2008). We 
also adjusted models simultaneously for aromatase inhibitor use (with or without 
tamoxifen), chemotherapy with an alkylating agent, and radiotherapy. Numbers of 
contralateral breast cancer cases, RRs and 95% CIs may be found in Supplementary Table 2.
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Cumulative incidence of contralateral breast cancer adjusted for competing risks by 
tamoxifen use and duration among 3,732 women who survived 5+ years after being 
diagnosed with an ER-positive first breast cancer.
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